Abstract
It is well established that pseudouridine (Ψ) and its derivative N(1)-methylpseudouridine (m(1)Ψ) suppress unwanted immunogenicity of RNA-based therapeutics. However, molecular mechanisms governing such immune evasion remain elusive. In a recent article, Bérouti, Wagner, and colleagues show that Ψ impairs the processing of Toll-like receptor (TLR)-agonistic ligands and hinders TLR activation.